Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALCNASDAQ:CVKDNASDAQ:IMCCNASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$1.62+2.5%$1.73$1.42▼$5.97$22.08M1.2441,880 shs21,507 shsCVKDCadrenal Therapeutics$12.29-1.2%$14.24$5.70▼$22.90$25.53M0.9542,596 shs20,178 shsIMCCIM Cannabis$2.91+10.0%$2.35$1.29▼$7.12$5.89M2.1995,453 shs118,842 shsOVIDOvid Therapeutics$0.34+4.1%$0.31$0.24▼$1.47$23.50M0.13434,142 shs283,192 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica+2.47%+13.22%-0.67%-11.04%-62.00%CVKDCadrenal Therapeutics-1.21%+19.55%-10.23%-24.00%+1,228,999,900.00%IMCCIM Cannabis+10.04%+4.50%+0.87%+112.04%+3.68%OVIDOvid Therapeutics+4.08%+0.29%+15.17%+22.16%-54.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALCCalciMedica3.2571 of 5 stars3.54.00.00.02.63.30.0CVKDCadrenal Therapeutics3.0342 of 5 stars3.55.00.00.01.11.70.6IMCCIM Cannabis0.3698 of 5 stars0.05.00.00.00.60.00.0OVIDOvid Therapeutics4.4801 of 5 stars3.63.00.04.62.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 3.00Buy$18.001,011.80% UpsideCVKDCadrenal Therapeutics 3.00Buy$32.00160.37% UpsideIMCCIM Cannabis 0.00N/AN/AN/AOVIDOvid Therapeutics 3.20Buy$3.13808.43% UpsideCurrent Analyst Ratings BreakdownLatest IMCC, CVKD, CALC, and OVID Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025OVIDOvid TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.00 ➝ $1.505/16/2025CVKDCadrenal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.005/15/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/24/2025OVIDOvid TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A$1.07 per shareN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/AIMCCIM Cannabis$39.44M0.30N/AN/A$1.03 per share2.82OVIDOvid Therapeutics$570K42.92N/AN/A$0.96 per share0.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$13.70M-$1.56N/AN/AN/AN/A-171.81%-100.43%8/11/2025 (Estimated)CVKDCadrenal Therapeutics-$10.65M-$9.26N/AN/AN/AN/A-244.94%-181.94%8/6/2025 (Estimated)IMCCIM Cannabis-$7.72M-$0.64N/AN/AN/A-9.10%-122.96%-11.69%8/13/2025 (Estimated)OVIDOvid Therapeutics-$26.43M-$0.35N/AN/AN/A-4,562.23%-34.17%-25.34%8/12/2025 (Estimated)Latest IMCC, CVKD, CALC, and OVID EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IMCCIM Cannabis-$0.2540$0.06+$0.3140$0.06$11.45 million$8.69 million5/14/2025Q1 2025CALCCalciMedica-$0.43-$0.36+$0.07-$0.36N/AN/A5/13/2025Q1 2025OVIDOvid Therapeutics-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million5/8/2025Q1 2025CVKDCadrenal Therapeutics-$1.64-$2.09-$0.45-$2.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AIMCCIM CannabisN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedica0.795.665.66CVKDCadrenal TherapeuticsN/A4.324.32IMCCIM Cannabis0.100.720.59OVIDOvid Therapeutics0.224.934.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/ACVKDCadrenal Therapeutics7.92%IMCCIM Cannabis7.68%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%CVKDCadrenal Therapeutics48.62%IMCCIM Cannabis5.91%OVIDOvid Therapeutics13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3013.97 million8.17 millionNo DataCVKDCadrenal Therapeutics41.97 million1.01 millionNot OptionableIMCCIM Cannabis3404.04 million2.10 millionNot OptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableIMCC, CVKD, CALC, and OVID HeadlinesRecent News About These CompaniesOvid Therapeutics Inc Chart - MorningstarJuly 2 at 11:32 AM | morningstar.comMJuneberry Farm in Ovid opens for u-pick seasonJuly 1 at 12:46 PM | fingerlakes1.comFOvid man, 81, charged with DWI after near-crashJune 28, 2025 | fingerlakes1.comFOvid Therapeutics To Sell Future Royalties Of Ganaxolone For $7 Mln In Cash, Stock Up In Pre-Market - NasdaqJune 27, 2025 | nasdaq.comOvid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 Million - NasdaqJune 27, 2025 | nasdaq.comOvid Therapeutics Inc.: Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone RoyaltiesJune 25, 2025 | finanznachrichten.deOvid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 MillionJune 25, 2025 | quiverquant.comQOvid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone RoyaltiesJune 25, 2025 | globenewswire.comAre These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?June 20, 2025 | msn.comOvid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025June 5, 2025 | taiwannews.com.twTOvid Therapeutics Inc. to Host Event on Biomarkers in Epilepsy featuring Dr. Alexander RotenbergJune 5, 2025 | quiverquant.comQOvid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comOvid Therapeutics Reports Business Updates and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comPhoreMost makes key appointments to Board to advance development of next-generation degrader therapeuticsMay 8, 2025 | cambridgenetwork.co.ukCOvid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 6, 2025 | zacks.comOvid Police Chief, city accused of civil rights violationsApril 24, 2025 | msn.comOvid Therapeutics (OVID) Receives a Buy from TD CowenApril 23, 2025 | theglobeandmail.comBiotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA CutsApril 10, 2025 | biospace.comBOvid's Main Street Business Owners Are Speaking Out About Recovery Process After January FireApril 5, 2025 | weny.comWOvid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMCC, CVKD, CALC, and OVID Company DescriptionsCalciMedica NASDAQ:CALC$1.62 +0.04 (+2.47%) As of 07/3/2025 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Cadrenal Therapeutics NASDAQ:CVKD$12.29 -0.15 (-1.21%) Closing price 07/3/2025 02:45 PM EasternExtended Trading$12.64 +0.35 (+2.85%) As of 07/3/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.IM Cannabis NASDAQ:IMCC$2.90 +0.27 (+10.04%) Closing price 07/3/2025 03:39 PM EasternExtended Trading$2.88 -0.03 (-1.03%) As of 07/3/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.Ovid Therapeutics NASDAQ:OVID$0.34 +0.01 (+4.08%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.35 +0.01 (+2.91%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
